A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. (NCT06916806)
An Open-label, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 Following Single-ascending Dose and Step-up Dose Administration to Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis
๐ฉบ Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the safety, tolerability, PK, and PD of AZD5492 administered subcutaneously in adult participants with SLE or IIM or RA Study details include: โข The study duration will be a minimum of 180 days in addition to the screening period. Additional follow-up visits may be required up to 12 months from study start. * Depending on the study part they are assigned to, participants will be administered AZD5492 once (Part 1) or twice (Part 2). * Study visits will occur at: Screening, Days 1-4, 8, 15, 22, 30, 60, 90, 120, 150, and 180 in Part 1, Screening, Days 1-4, 8-11, 15, 22, 29, 43, 60, 90, 120, 150, and 180 in Part 2.
Who can join: Review the eligibility criteria below.
Location: Research Site โ Anniston, Alabama
Age range: 18 Years to 70 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- Research Site โ Anniston, Alabama
- Research Site โ Birmingham, Alabama
- Research Site โ La Jolla, California
- Research Site โ Sacramento, California
- Research Site โ Iowa City, Iowa
- Research Site โ Omaha, Nebraska
- Research Site โ Chapel Hill, North Carolina
- Research Site โ Hamilton, Ontario
- Research Site โ Sherbrooke, Quebec
- Research Site โ Beijing,
- Research Site โ Shanghai,
- Research Site โ Wuhan,
- Research Site โ Zhengzhou,
- Research Site โ Bordeaux,
- Research Site โ Montpellier,
- Research Site โ Nancy,
- Research Site โ Paris,
- Research Site โ Strasbourg,
- Research Site โ Toulouse,
- Research Site โ Cologne,
- Research Site โ Erlangen,
- Research Site โ Magdeburg,
- Research Site โ Pok Fu Lam,
- Research Site โ Bunkyล City,
- Research Site โ Kita-gun,
๐ Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Lupus Erythematosus
- A Study of Obexelimab in Patients With Systemic Lupus Erythematosus โ Peoria, Arizona
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus โ Anniston, Alabama
- REACH (Restore Energy, Activity Can Help) Lupus Study โ Boston, Massachusetts
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus โ Birmingham, Alabama
- A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice โ Innsbruck, Tyrol
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) โ Birmingham, Alabama
Explore by condition: All Systemic Lupus Erythematosus clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.